Press Releases
PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder FDA Fast Track designation granted Topline results anticipated mid-2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 17, 2022-- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS
SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Jun. 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other
VistaGen will present at upcoming William Blair 42 nd Annual Growth Stock Conference and Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused
VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder
May 05, 2022
The FDA agreed that data from nonclinical and clinical studies of PH94B completed to date provide no signal of abuse potential The FDA also agreed that additional nonclinical studies are not necessary to evaluate the abuse potential of PH94B and, at this time, based on studies completed to date, a
May 02, 2022
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and
Apr 21, 2022
Research presented at the Annual Meeting of the Society of Biological Psychiatry and of the American Society of Clinical Psychopharmacology highlight fundamentally differentiated mechanism of action for PH94B These preclinical data demonstrate that intranasal radiolabelled-PH94B is largely
Apr 12, 2022
Companies plan to initiate the global study of PH94B for the acute treatment of social anxiety disorder (SAD) in the second half of 2022 Trial designed to support commercialization of PH94B in China and other markets outside the U.S. SOUTH SAN FRANCISCO, Calif. & SHANGHAI --(BUSINESS WIRE)--Apr.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other central
Feb 10, 2022
Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to evaluate PH94B in social anxiety disorder (SAD) that are expected in mid-2022 and second half 2022, respectively; PALISADE Long-term Safety Study
Displaying 41 - 50 of 233